Witnessing the stock’s movement on the chart, on Wednesday Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) had a quiet start as it plunged -5.26% to $1.08, before settling in for the price of $1.14 at the close. Taking a more long-term approach, ADAP posted a 52-week range of $0.42-$2.05.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 134.88%. Meanwhile, its Annual Earning per share during the time was 10.30%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -467.56%. This publicly-traded company’s shares outstanding now amounts to $227.17 million, simultaneously with a float of $200.15 million. The organization now has a market capitalization sitting at $245.34 million. At the time of writing, stock’s 50-day Moving Average stood at $1.3813, while the 200-day Moving Average is $0.8949.
Adaptimmune Therapeutics Plc ADR (ADAP) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Adaptimmune Therapeutics Plc ADR’s current insider ownership accounts for 11.90%, in contrast to 62.39% institutional ownership. According to the most recent insider trade that took place on Jan 17 ’24, this organization’s Chief Executive Officer sold 30,080 shares at the rate of 0.67, making the entire transaction reach 20,244 in total value, affecting insider ownership by 44,848. Preceding that transaction, on Jan 17 ’24, Company’s Chief Operating Officer sold 18,908 for 0.67, making the whole transaction’s value amount to 12,725. This particular insider is now the holder of 7,785 in total.
Adaptimmune Therapeutics Plc ADR (ADAP) Earnings and Revenue Records
Adaptimmune Therapeutics Plc ADR’s EPS decrease for this current 12-month fiscal period is -467.56% and is forecasted to reach -0.59 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 1.00% through the next 5 years, which can be compared against the 10.30% growth it accomplished over the previous five years trading on the market.
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Trading Performance Indicators
Let’s observe the current performance indicators for Adaptimmune Therapeutics Plc ADR (ADAP). It’s Quick Ratio in the last reported quarter now stands at 2.85. The Stock has managed to achieve an average true range (ATR) of 0.13. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 4.04.
In the same vein, ADAP’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.52, a figure that is expected to reach -0.15 in the next quarter, and analysts are predicting that it will be -0.59 at the market close of one year from today.
Technical Analysis of Adaptimmune Therapeutics Plc ADR (ADAP)
Going through the that latest performance of [Adaptimmune Therapeutics Plc ADR, ADAP]. Its last 5-days volume of 1.49 million was inferior to the volume of 1.77 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 45.90% While, its Average True Range was 0.1274.
Raw Stochastic average of Adaptimmune Therapeutics Plc ADR (ADAP) in the period of the previous 100 days is set at 40.12%, which indicates a major rise in contrast to 37.94% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 104.03% that was lower than 109.93% volatility it exhibited in the past 100-days period.
